Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
Study First Submitted
Endpoints
Primary
Prevalence of CYP2C19*2, CYP2C19*3, and CYP2C19*17 Genetic Variants
Timeframe: At enrollment, using peripheral blood samples collected during the study.
Secondary (1)
Association Between CYP2C19 Genetic Variants and Major Adverse Cardiovascular Events (MACE)
Arms and interventions
Egyptian Patients Receiving Clopidogrel After PCI
Approximately 1,000 Egyptian adults aged 18 years or older undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel as part of antiplatelet therapy will be enrolled from multiple cardiac catheterization centers across Egypt. Eligible patients may present with STEMI, NSTEMI, or unstable angina, according to the study eligibility criteria. Demographic information, medical history, cardiovascular characteristics, concomitant medications, and clinical outcomes will be collected prospectively. Approximately 3 mL of peripheral blood will be collected for DNA extraction and genotyping of CYP2C19\*2 (rs4244285), CYP2C19\*3 (rs4986893), and CYP2C19\*17 (rs12248560) using TaqMan real-time PCR. This is an observational study; no study-assigned intervention will be administered, and antiplatelet treatment will be determined by the treating healthcare team.
